Oncoquest Inc.
Records under this name other than patents Oncoquest Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,697,079 | Ige Antibodies for the Treatment of Cancer Formerly held In force · High confidence | In force | High confidence | |
| US 8,945,566 | METHODS FOR IMPROVING THE BIOACTIVITY OF THERAPEUTIC IgE ANTIBODIES FOR THE TREATMENT OF DISEASE Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,392,444 | Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,975,163 | Methods of increasing delivery of anti-cancer agents to targets Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,537,636 | Treatment of Cancer with Therapeutic Monoclonal Antibody Specific for a Tumor Associated Antigen and an Immune Adjuvant Formerly held In force · High confidence | In force | High confidence | |
| US 11,351,255 | Treatment of Cancer with Therapeutic Monoclonal Antibody Specific for a Tumor Associated Antigen and an Immune Adjuvant Formerly held In force · High confidence | In force | High confidence | |
| US 7,147,850 | Therapeutic Binding Agents Against MUC-1 Antigen and Methods for Their Use Formerly held Term ended Ended no later than Oct 13, 2021 · Low confidence | Term ended | Ended no later than Oct 13, 2021 | Low confidence |
| US 6,689,355 | Therapeutic Method and Composition Utilizing Antigen-Antibody Complexation and Presentation by Dendritic Cells Formerly held Term ended Term ended May 11, 2021 · High confidence | Term ended | Term ended May 11, 2021 | High confidence |
| US 8,038,994 | Combination therapy for treating disease Formerly held Term ended Term ended Apr 2, 2021 · From the USPTO record | Term ended | Term ended Apr 2, 2021 | From the USPTO record |
| US 6,716,966 | Therapeutic binding agents against MUC-1 antigen and methods for their use Formerly held Term ended Term ended Aug 18, 2020 · From the USPTO record | Term ended | Term ended Aug 18, 2020 | From the USPTO record |